Dr. Colin Reisner is CEO of Pearl Therapeutics, Inc. and Head of Respiratory Global Medicines, AstraZeneca. He is an innovative leader with more than 20 years of international experience at top-tier companies, including Boehringer Ingelheim, GSK and Novartis.
In 2007, Colin joined Pearl Therapeutics in its very early stages, where he helped raise over $150 million, expanded the company from five employees to more than 250 employees, designed the clinical development strategy that advanced Bevespi Aerosphere from concept to NDA filing in 7 ½ years, followed by a first-cycle approval by the FDA. This same approach was leveraged to accelerate the PT010 Triple MDI program from Phase I to Phase III in under two years.
As Head of Respiratory Global Medicines, AstraZeneca, Colin is actively involved in all late stage respiratory clinical programs, including the inhaled, oral and biologics programs.
Colin received his medical school training (MBBCH degree) from the University of Witwatersrand, Johannesburg, South Africa. He received specialist training in internal medicine at a Yale affiliated program, followed by sub-specialty training in Allergy Immunology at National Jewish in Denver, CO. He previously held adjunct faculty positions at Yale and at Duke University. He has published extensively, and is a fellow of the American College of Chest Physicians, a Fellow of the American Academy of Allergy Asthma & Immunology, is an active member of ATS.